No profile data available.
EyePoint Pharmaceuticals, Inc. (EYPT) is a healthcare company in the eye treatment pharmaceuticals industry, based in Watertown, United States, with about 214 full-time employees.
It reported revenue of $43.27 million for fiscal year 2024, down 6.0% from fiscal year 2023, and net income of -$130.87 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $966,000, down 90.8% from a year before. United States was its largest region in fiscal year 2025, with 96% of revenue. Its market capitalization was $293.12 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
EyePoint Pharmaceuticals reported $43.27 million in revenue for fiscal year 2024, down 6.0% from $46.02 million in fiscal year 2023. In Q3 2025 revenue was $966,000.
United States: 96% of revenue by region in fiscal year 2025, followed by China (4%).
$293.12 million as of October 9, 2026.
Listed companies of a similar size in the same industry (eye treatment pharmaceuticals) include Opus Genetics, Inc. (IRD), Surrozen, Inc. (SRZN), Ocugen, Inc. (OCGN), Lineage Cell Therapeutics, Inc. (LCTX).